The "gender factor" in wearing-off among patients with parkinson's disease: A post hoc analysis of DEEP study by Colombo, Delia et al.
Research Article
The ‘‘Gender Factor’’ in Wearing-Off among Patients with
Parkinson’s Disease: A Post Hoc Analysis of DEEP Study
Delia Colombo,1 Giovanni Abbruzzese,2 Angelo Antonini,3 Paolo Barone,4
Gilberto Bellia,1 Flavia Franconi,5 Lucia Simoni,6 Mahmood Attar,1 Emanuela Zagni,1
Shalom Haggiag,7 and Fabrizio Stocchi8
1Novartis Farma S.p.A., Origgio, Varese 21040, Italy
2Department of Neurosciences, University of Genoa, Genoa 16132, Italy
3Department of Parkinson’s Disease, IRCCS San Camillo, Venice 30126, Italy
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Background. The early detection of wearing-off in Parkinson disease (DEEP) observational study demonstrated that women with
Parkinson’s disease (PD) carry an increased risk (80.1%) for wearing-off (WO). This post hoc analysis of DEEP study evaluates
gender differences on WO and associated phenomena.Methods. Patients on dopaminergic treatment for ≥1 year were included in
this multicenter observational cross-sectional study. In a single visit, WO was diagnosed based on neurologist assessment as well
as the use of the 19-item wearing-off questionnaire (WOQ-19); WOwas defined for scores ≥2. Post hoc analyses were conducted to
investigate gender difference for demographic and clinical features with respect to WO. Results. Of 617 patients enrolled, 236 were
women and 381 were men. Prevalence of WO was higher among women, according to both neurologists’ judgment (61.9% versus
53.8%, 𝑃 = 0.045) and theWOQ-19 analysis (72.5% versus 64.0%, 𝑃 = 0.034). In patients withWO (WOQ-19), women experienced
≥1 motor symptom in 72.5% versus 64.0% in men and ≥1 nonmotor symptom in 44.5% versus 36.7%, in men. Conclusions. Our
results suggest WO as more common among women, for both motor and nonmotor symptoms. Prospective studies are warranted
to investigate this potential gender-effect.
1. Background
Parkinson’s disease (PD) is one of the most common age-
related progressive neurodegenerative disorders, with no
identifiable cause. PD is slightly more common in men than
in women in most studies, usually ranging from a 1.2 : 1 ratio
up to a 1.5 : 1 ratio [1], and men seem to be at higher risk
for PD [2–4]. The reasons for the increased risk in men are
not known; probably “male lifestyle” could account for some
of the excess incidence in men [5]. Alternatively, there is
increasing evidence from in vitro as well as clinical studies in
humans that estrogenmay be neuroprotective [6]. Sex-related
differences have been reported in the onset of symptoms and
type of motor symptoms as well as in medication use [7,
8]. Notably, normal human basal ganglia, specifically within
the dopamine system, are sexually dimorphic and that may
influence the onset and progression of PD [8].
Levodopa is the most efficacious treatment in the man-
agement of PD. Unfortunately, chronic use of traditional
levodopa/dopa decarboxylase inhibitor formulations is asso-
ciated with the development of motor complications, such as
wearing-off (WO) and dyskinesia that occur in the majority
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of PD patients. The WO effect, or end-of-dose failure,
refers to a decrease in the length of time that each dose
of levodopa controls symptoms. “Off” states that result in
motor and nonmotor symptoms, freezing of gait (FOG), and
falling are disabling for many patients. Considered to be
the major source of disability in PD patients, recognition of
these complications is critical in order to develop different
strategies designed not only to treat these problems when
they develop, but also to prevent troublesome complications
associated with potential risk factors.
We previously conducted an observational, cross-
sectional, multicenter study called Early DEtection of
wEaring off in Parkinson disease (DEEP Study) [9, 10].
The primary goal was to look at the frequency of WO
phenomena among a wide population of Italian patients
with PD and secondly to assess associated phenomena,
such as FOG and nonmotor symptoms, as well as assessing
the impact on patient’s QoL. In our sample WO occurred
since the early years of the disease; furthermore younger
age, unified Parkinson’s disease rating scale (UPDRS) part
II score, duration of anti-Parkinson (APD) treatment, and
female gender were found significantly associated with WO.
Our data showed women having an 80.1% higher risk of
experiencing WO than men [9]. This exploratory study
aimed to further examine what role the “gender factor” in
WO would play, that is, to characterize disparities between
women andmen in frequency and features ofWO symptoms.
For this purpose, we conducted a post hoc analysis of the
DEEP study database. This study is also part of the gender-
medicine project (METAGEM), being carried out with the
aim to describe clinical outcomes and therapeutic approach
by gender, through the analysis of observational studies
conducted in Italy, among different therapeutic areas [11].
2. Methods
Patients prospectively recruited were men and women aged
18 years or older, with PD (Hoehn and Yahr Stages 1–
5), nondemented, under levodopa (LD), and/or dopamine
agonists (DAs) therapy for ≥1 year before the study screening.
The full DEEP study design, including complete inclu-
sion/exclusion criteria, has been published [9]. The study
was conducted in accordance with Good Clinical Practice
and the Declaration of Helsinki. The study protocol and
amendments were approved by each local Ethics Committees
or Institutional Review Boards of all 37 participating centers
(both academic and hospital based) across Italy (Additional
file 1). All patients provided written, informed consent before
study participation.
During a single visit, neurologists experienced in move-
ment disorders and previously subjected to targeted training
acquired standard demographic and detailed clinical infor-
mation on all participants who met the criteria, via a struc-
tured interview and by examination. Therapy was expressed
in terms of Levodopa equivalent daily dose (LEDD) [12].
Subjects were assessed with the UPDRS and the Hoehn and
Yahr scale (H&Y). The diagnosis of WO was made on both
the neurologist evaluation and the basis of the patient self-
assessment using the Italian version of the 19-item Wearing-
Off Questionnaire (WOQ-19) [10]. The WOQ-19 consists of
9 items assessing fluctuations of motor symptoms, including
tremor, difficulty in speech, weakness, problems with bal-
ance, slowness, reduced dexterity, general stiffness, muscle
cramps, and difficulty getting out of the chair and 10 items
assessing fluctuations of nonmotor symptoms, including
anxiety, sweating, mood changes, numbness, panic attacks,
cloudy mind/dullness of thinking, abdominal discomfort,
experience hot and cold, pain, and aching [10]. For each item,
patients were asked to tick whether symptoms were present
and whether they improved after the following dose of anti-
Parkinson treatment: a cutoff of ≥2 improved symptoms has
been previously established to make diagnosis of WO [10].
3. Statistical Analysis
Descriptive analyses were mean and standard deviation (SD)
or median and interquartile range (IQR). Only the fully
completed scales were considered evaluable for the statistical
analysis. Gender differences analyses were performed on all
patients who responded to inclusion-exclusion criteria. Dif-
ferences in demographics/baseline characteristics between
patients withWOand patients with noWO (as assessed using
WOQ-19 and the neurologist assessment) were estimated
using 𝑡-test for continuous data and the Chi-square test for
categorical data. As post hoc analyses, all P values presented
are exploratory. Patients withmissing data in selected param-
eters were not evaluated for those parameters. All analyses
were performed with SAS v. 9.2 and Enterprise Guide 4.3.
4. Results
Of the 634 patients screened, 617 (97.3%) met the inclusion
criteria: 236 (38.2%) were women and 381 (61.8%) were men
(Table 1). The excluded patients did not differ significantly
on demographic or clinical parameters with respect to the
study population [9]. Baseline demographic data are pro-
vided in Tables 1 and 2. Evaluation of gender differences in
the study sample indicated no difference in age, history of
concomitant diseases, caregiver support, body mass index,
or coffee consumption. As shown in Table 1, women were
less likely to be married/cohabiting (𝑃 = 0.0001) and have
less education (𝑃 = 0.0002). In almost the third of cases
women were housewives and were less likely to be employed
(𝑃 = 0.0046). Men were more likely to be past (𝑃 < 0.0001)
or current smokers (𝑃 = 0.0059) and to be frequent alcohol
consumers (𝑃 < 0.0001), although more often engaged in
physical activity on a regular basis (𝑃 = 0.0005).
A shown in Table 2, disease duration, H&Y staging, and
UPDRS andMMSE scores were statistically indistinguishable
between both groups. Postural instability/gait difficulties
(PIGD) phenotype was found in 53.0% of the whole sample,
although more prevalent in women (57.0% versus 50.5%, 𝑃 =
0.005), while the tremor dominant (TD) phenotypewasmore
frequently attributed tomen (29.0% versus 41.4%,𝑃 = 0.005).
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Age, mean ± SD 67.0 ± 8.9 66.6 ± 9.4 0.6602
Marital status,𝑁 (%)#
Married/cohabiting 168 (71.2) 321 (84.3) 0.0001
Single 16 (6.8) 27 (7.1)
Divorced/separated 5 (2.1) 13 (3.4)
Widowed 46 (19.5) 15 (3.9)
Employment status,
𝑁 (%)
Employed 23 (9.7) 69 (18.1) 0.0046
Unemployed 1 (0.4) 6 (1.6)
Retired 130 (55.1) 288 (75.6)
Housewife 75 (31.8) —
Other 7 (3.0) 18 (4.7)
Education,𝑁 (%) 0.0002
≤5 years 109 (46.2) 113 (29.7)
6–8 years 54 (22.9) 122 (32.0) 0.0002
>8 years 73 (30.9) 146 (38.3) 0.0008
Caregiver assistance,
𝑁 (%) 49 (20.8) 63 (16.5) 0.2050
Smoking habit,𝑁
(%)# <0.0001
Smokers 15 (6.4) 37 (9.7) 0.0059
Ex-smokers 32 (13.6) 149 (39.1) <0.0001
Nonsmokers 183 (77.5) 189 (49.6)
Coffee consumers,𝑁
(%) 162 (68.6) 264 (69.3) 0.6622
Alcohol consumers,
𝑁 (%) 84 (35.6) 240 (63.0) <0.0001
Regular physical
activity,𝑁 (%) 55 (23.3) 140 (36.7) 0.0005
BMI, mean ± SD 24.9 ± 4.5 26.4 ± 3.5
Concomitant
diseases,𝑁 (%) 145 (61.4) 205 (53.8) 0.0764
Hypertension 75 (31.8) 109 (28.6)
Ischemic heart
Disease 91 (38.6) 137 (36.0)
Diabetes mellitus 20 (8.5) 34 (8.9)
Neoplasms 7 (3.0) 13 (3.4)
Cerebrovascular
disease 5 (2.1) 4 (1.0)
Obesity 3 (1.3) 7 (1.8)
Psychiatric
disorders 9 (3.8) 9 (2.4)
Other 57 (24.2) 72 (18.9)
#Missing data for <10 patients/variable.
Prevalence of WO was higher among women, accord-
ing to both neurologists’ judgment (61.9% versus 53.8%,
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Figure 1: Rates ofWO diagnosis according toWOQ-19 stratified by
disease duration: women versus men.
𝑃 = 0.034) (Figure 1). Taking into account the symptoms
reported as usually improving after the following dose of
anti-Parkinson agents (APD), otherwise defined as WO
symptoms, 3.3 ± 2.5 versus 3.0 ± 2.6 were motor symptoms
(𝑃 = 0.222) and 1.2 ± 1.8 versus 0.9 ± 1.5 were nonmotor
symptoms (𝑃 = 0.0125), respectively, in women and men.
The frequency of symptoms reported by patients through the
WOQ-19, stratified by gender and disease duration, is listed
in Table 3. Among patients with a diagnosis ofWO according
toWOQ-19, women experienced≥1motor symptom in 72.5%
versus 64.0% in men and ≥1 nonmotor symptom in 44.5%
versus 36.7%, respectively, in men (Figure 2).
With regard to APD therapy, no differences were
observed in the use of the different classes of APDs (𝑃 =
0.4457) or for LEDD values (844.2 ± 679.0 versus 874.4 ±
749.1, 𝑃 = 0.622).
Finally, women reported significantly higher PDQ-8
scores than men (31.3 ± 18.4 versus 27.7 ± 19.1, 𝑃 = 0.023).
5. Discussion
WO is an important feature of PD, often marking the end
of the “honeymoon period.” The WO manifestations can be
extremely heterogeneous from subject to subject, and early
recognition allows timely optimization of treatment that may
impact patient care and long-term clinical outcomes. The
reasons underlying these complications are not fully under-
stood and well-recognized risk factors for the development
of WO and dyskinesias include young age at onset, low body
weight, severity of disease higher levodopa dose, association
of levodopa with entacapone, once daily intake of levodopa,
duration of levodopa therapy, more severe UPDRS Part II,
and female gender [9, 13–15]. This paper was dedicated to
assess gender differences in WO and is based on the post
hoc analysis of the DEEP study, a large epidemiological
survey that enrolled more than 600 patients with PD across
Italy. This study specifically investigated for WO and shows
that women are more likely to suffer from WO symptoms
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mean ± SD 0.389
<5 years,𝑁 (%) 66 (28.0) 119 (31.2)
>5 years,𝑁 (%) 170 (72.0) 262 (68.8)
H&Y,𝑁 (%)# 0.291
≤2 134 (56.8) 233 (61.1)
≥2.5 101 (42.8) 148 (38.6)
UPDRS total score,
mean ± SD 36.2 ± 17.7 38.1 ± 17.4 0.223
Part I 2.3 ± 2.0 2.1 ± 1.9 0.287
Part II 11.1 ± 6.4 11.3 ± 6.0 0.621
Part III 23.0 ± 11.6 24.6 ± 11.8 0.129
PD subtypes,𝑁 (%)§ 0.006
TD 62 (26.3) 142 (37.3)
PIGD 120 (50.8) 172 (45.1) 0.0149
IND 29 (12.3) 28 (7.3) 0.0041
MMSE, mean ± SD 28.1 ± 1.67 28.2 ± 1.62 0.306
Anti-Parkinson drugs
classes,𝑁 (%) 0.4457
LD monotherapy 29 (12.3) 35 (9.2)
DA monotherapy 11 (4.7) 15 (3.9)
LD + DA 152 (64.4) 234 (61.4)
MAOIs 84 (35.6) 157 (41.2)
COMT inhibitors 79 (33.5) 132 (34.6)
LEDD, mg mean ± SD 844.2 ± 679.0 874.4 ± 749.1 0.622
Diagnosis of WO by
neurologists,𝑁 (%) 146 (61.9) 205 (53.8) 0.0495
<5 years disease
duration 21 (31.8) 38 (31.9) 0.987
>5 years disease
duration 125 (73.5) 167 (63.7) 0.034
Diagnosis of WO by
WOQ-19,𝑁 (%) 171 (72.5) 244 (64.0) 0.034
<5 years disease
duration 37 (56.1) 57 (47.9) 0.2875
>5 years disease
duration 134 (78.8) 187 (71.4) 0.0834
PDQ-8, mean ± SD 31.3 ± 18.4 27.7 ± 19.1 0.023
SD: standard deviation; H&Y: Hoehn and Yahr staging; UPDRS: unified
Parkinson’s disease rating scale; PD: Parkinson’s disease; TD: tremor dom-
inant; PIGD: postural instability and gait difficulties; IND: intermediate;
MMSE: mini-mental state examination; LD: levodopa; DA: dopamine-
agonist; MAOIs: monoamine oxidase B inhibitors; COMT: catechol-O-
methyltransferase; LEDD: levodopa equivalent daily dose; WO: wearing-
off; WOQ-19: 19-item wearing-off questionnaire; PDQ-8: 8-item Parkinson’s
disease questionnaire.
§PD subtypes could not be calculated for 39 males and 25 females. Paired
post hoc Chi-squares take TD as reference.
#Missing data for <10 patients/variable.
as compared to men and that female gender confers an
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Figure 2: Rates of motor and nonmotor WO symptoms: women
versus men.
confirmed both by the neurologist assessment (61.9% versus
53.8%, 𝑃 = 0.049) and by patients themselves thorough the
WOQ-19 (72.5% versus 64.0%, 𝑃 = 0.034). Among patients
with WO (WOQ-19), women more frequently complained
of ≥1 motor (72.5% versus 64.0%) and ≥1 nonmotor (44.5%
versus 36.7%) symptoms of WO. Our findings have been
supported in a previous clinic-based sample of patients with
PD, where WO symptoms have been shown to occur more
frequently in women (46% versus 29%, 𝑃 = 0.02) [16].
Furthermore, durations to develop WO and dyskinesia were
shown to be shorter in women compared to men, as well
as disease progression being slightly faster for women [17].
A similar “gender effect” has already been shown for the
occurrence of levodopa-induced dyskinesias, as it has been
claimed that dyskinesias occur more frequently in women
if disease duration is >5 years [18, 19] and with a shorter
time latency than men [20]. Otherwise, in a large British
community-based study, men and women did not differ in
the occurrence of motor fluctuations or dyskinesias [13].
In a recent post hoc analysis of a large prospective trial,
female gender was identified as a specific predicting factor for
dyskinesias and WO as well, and the authors hypothesized
that it would reflect increased levodopa concentrations in
women because of lower body weight [15]. This interesting
hypothesis, in addition to providing an explanation of the
association with female gender, would place the emphasis
on a parameter, such as body weight, which in clinical
practice is generally overlooked for therapy decisions. Data
available fromour observational study do not allow analyzing
this aspect, as patients were undergoing very heterogeneous
treatments and were poorly comparable to one another.
In DEEP population women and men were substantially
homogeneous for age, disease duration, H&Y staging, and
neurological disability (UPDRS; MMSE); otherwise smoking
habits, alcohol consumption, and physical activity differed,
and this reflects what is observed in the general population
[21]. To our knowledge no data indicate a direct association
of these social factors with WO; nevertheless, it is plausible
that theymight influence PD treatment and vice versa, andwe
cannot exclude possible association with the development of
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Table 3: Frequency of experienced symptoms and WO symptoms, as reported by DEEP population, through the WOQ-19, stratified by
disease duration: women versus men.
Disease duration
<5 years >5 years Total













Referred motor symptoms by WOQ-19, mean
± SD
Experienced 4.6 ± 2.2 4.8 ± 2.1 6.0 ± 1.9 5.9 ± 2.0 5.6 ± 2.1 5.5 ± 2.1
WO 2.0 ± 2.1 2.0 ± 2.4 3.8 ± 2.4 3.5 ± 2.6 3.3 ± 2.5 3.0 ± 2.6
Referred nonmotor symptoms by WOQ-19,
mean ± SD
Experienced 2.9 ± 2.0 2.3 ± 2.2 4.0 ± 2.3 3.0 ± 2.2 3.7 ± 2.3 2.8 ± 2.2
WO 0.7 ± 1.3 0.5 ± 1.1 1.4 ± 1.9 1.1 ± 1.6 1.2 ± 1.8 0.9 ± 1.5
Experienced and WO symptoms, mean ± SD
Experienced 7.5 ± 3.6 7.1 ± 3.8 9.9 ± 3.6 8.9 ± 3.7 9.3 ± 3.8 8.3 ± 3.8
WO 2.7 ± 2.8 2.4 ± 3.1 5.2 ± 3.9 4.5 ± 3.8 4.5 ± 3.8 3.9 ± 3.7
Experienced and WO symptoms, 𝑛 (%)
Tremor
Experienced 48 (72.7) 81 (68.1) 117 (68.8) 180 (68.7) 165 (69.9) 261 (68.5)
WO 29 (43.9) 40 (33.6) 96 (56.5) 127 (48.5) 125 (53.0) 167 (43.8)
Difficulty in speech
Experienced 14 (21.2) 51 (42.9) 62 (36.5) 152 (58.0) 76 (32.2) 203 (53.3)
WO 8 (12.1) 21 (17.6) 28 (16.5) 76 (29.0) 36 (15.3) 97 (25.5)
Weakness
Experienced 48 (72.7) 72 (60.5) 129 (75.9) 184 (70.2) 177 (75.0) 256 (67.2)
WO 14 (21.2) 27 (22.7) 68 (40.0) 102 (38.9) 82 (34.7) 129 (33.9)
Problems with balance
Experienced 24 (36.4) 49 (41.2) 110 (64.7) 136 (51.9) 134 (56.8) 185 (48.6)
WO 7 (10.6) 18 (15.1) 48 (28.2) 64 (24.4) 55 (23.3) 82 (21.5)
Slowness of movements
Experienced 50 (75.8) 90 (75.6) 157 (92.4) 227 (86.6) 207 (87.7) 317 (83.2)
WO 27 (40.9) 42 (35.3) 122 (71.8) 153 (58.4) 149 (63.1) 195 (51.2)
Reduced dexterity
Experienced 36 (54.5) 85 (71.4) 143 (84.1) 219 (83.6) 179 (75.8) 317 (79.8)
WO 18 (27.3) 37 (31.1) 101 (59.4) 145 (55.3) 119 (50.4) 182 (47.8)
General stiffness
Experienced 22 (33.3) 49 (41.2) 98 (57.6) 168 (64.1) 120 (50.8) 217 (57.0)
WO 12 (18.2) 27 (22.7) 80 (47.1) 122 (46.6) 92 (39.0) 149 (39.1)
Muscle cramps
Experienced 36 (54.5) 57 (47.9) 100 (58.8) 138 (52.7) 136 (57.6) 195 (51.2)
WO 11 (16.7) 11 (9.2) 37 (21.8) 48 (18.3) 48 (20.3) 59 (15.5)
Difficulty getting out of chair
Experienced 24 (36.4) 36 (30.2) 98 (57.6) 137 (52.3) 122 (51.7) 173 (45.4)
WO 6 (9.1) 11 (9.2) 62 (36.5) 79 (30.1) 68 (28.8) 90 (23.6)
Anxiety
Experienced 42 (63.6) 49 (41.2) 112 (65.9) 123 (46.9) 154 (65.3) 172 (45.1)
WO 10 (15.1) 13 (10.9) 46 (27.1) 45 (17.2) 56 (23.7) 58 (15.2)
Sweating
Experienced 16 (24.2) 30 (25.2) 85 (50.0) 102 (38.9) 101 (42.8) 132 (34.6)
WO 3 (4.5) 4 (3.4) 19 (11.2) 28 (10.7) 22 (9.3) 32 (8.4)
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Table 3: Continued.
Disease duration
<5 years >5 years Total














Experienced 28 (42.4) 47 (39.5) 94 (55.3) 112 (42.7) 122 (51.7) 159 (41.7)
WO 8 (12.1) 12 (10.1) 44 (25.9) 47 (17.9) 52 (22.0) 59 (15.5)
Numbness
Experienced 11 (16.7) 19 (16.0) 53 (31.2) 52 (19.8) 64 (27.1) 71 (18.6)
WO 2 (3.0) 2 (1.7) 16 (9.4) 17 (6.5) 18 (7.6) 19 (5.0)
Panic attacks
Experienced 5 (7.6) 7 (5.9) 29 (17.1) 32 (12.2) 34 (14.4) 39 (10.2)
WO 1 (1.5) 1 (0.8) 11 (6.5) 9 (3.4) 12 (5.1) 10 (2.6)
Cloudy mind
Experienced 17 (25.7) 22 (18.5) 59 (34.7) 96 (36.6) 76 (32.2) 118 (31.0)
WO 4 (6.1) 3 (2.5) 21 (12.3) 41 (15.6) 25 (10.6) 44 (11.5)
Abdominal discomfort
Experienced 19 (28.8) 30 (25.2) 53 (31.2) 48 (18.3) 72 (30.5) 78 (20.5)
WO 1 (1.5) 2 (1.7) 11 (6.5) 13 (5.0) 12 (5.1) 15 (3.9)
Feelings of hot/cold
Experienced 11 (16.7) 16 (13.4) 51 (30.0) 53 (20.2) 62 (26.3) 69 (18.1)
WO 2 (3.0) 2 (1.7) 14 (8.2) 12 (4.6) 16 (6.8) 14 (3.7)
Pain
Experienced 29 (43.9) 26 (21.8) 73 (42.9) 75 (28.6) 102 (43.2) 101 (26.5)
WO 8 (12.1) 5 (4.2) 29 (17.1) 23 (8.8) 37 (15.7) 28 (7.3)
Aching
Experienced 14 (21.2) 31 (26.1) 67 (39.4) 88 (33.6) 81 (34.3) 119 (31.2)
WO 5 (7.6) 11 (9.2) 33 (19.4) 41 (15.6) 38 (16.1) 52 (13.6)
WOand contribution for the differences betweenwomen and
men. Large cohort studies would address these hypotheses.
DEEP women reported poorer QoL than men (𝑃 =
0.023), probably due to WO, as we have previously reported
that the number of motor symptoms (0.34008; 𝑃 < 0.0001)
and nonmotor symptoms of WO (0.33595; 𝑃 < 0.0001)
correlates with PDQ-8 score and that by linear regression
analysis the presence of each additional WO symptom, as
identified by WOQ-19, corresponds to an increase of 1.15
points of the PDQ-8 score (𝑃 < 0.0001) [9].
According to treatment guidelines in PD, the symp-
tomatic control of WO should be obtained by increasing
and fractionating the dose of levodopa or by the addition
of other drugs, such as DAs, catechol-O-methyl transferase
(COMT) inhibitors, or monoamine oxidase inhibitors [22–
24]. Surprisingly, in front of the higher prevalence of WO,
DEEP women were indistinctly treated as men, both in terms
of classes of APD and by LEDD analysis. This could have
several explanations. First, women and men may exhibit
different pharmacological response to APD, making a direct
comparison between women and men difficult. Although
gender differences are generally not acknowledged in pub-
lished clinical guidelines of PD management, evidence of
gender disparities inmedication response, pharmacokinetics,
and tolerability suggests the need for payingmore attention to
differences betweenwomen andmen in clinicalmanagement.
Levodopa treatment has been found to significantly improve
motor function in women more than in men [25]. Studies
suggest that women have greater levodopa bioavailability
[26, 27] and different clearance of dopaminergic agents,
which may play a role in gender-specific dosing of PD
medications and may explain why women are more likely
to have levodopa-related dyskinesias [18, 19, 28]. The COMT
inhibitors have also been reported to have different tolerabil-
ity profiles based on gender, whichmay result fromdisparities
in optimal levodopa dosage [29, 30].
Second, the higher frequency of WO among women
may reflect a state of undertreatment. If this is the case,
we may interpret it as a more “gentle” treatment approach
adopted for women with PD, compared to men, perhaps
due to safety and tolerability concerns. This hypothesis is
in line with the findings of a large population-based study
including more than 25,000 patients with PD (Thomson
Reuter’s Marketscan), as men were found to be more likely to
be treated with an APD in the first year after diagnosis (72.9%
versus 67.5%, 𝑃 < 0.0001) and to be treated adjunctively with
The Scientific World Journal 7
Table 4: Members of the DEEP study group.
First name Last name Affiliation City
Fabrizio Stocchi Dipartimento di Neurologia IRCCS San Raffaele Pisana di Roma Roma
Laura Vacca Dipartimento di Neurologia IRCCS San Raffaele Pisana di Roma Roma
Peter P. Pramstaller Neurologia Ospedale di Bolzano Bolzano
Maurizio Facheris Neurologia Ospedale di Bolzano Bolzano
Mario Guidotti Neurologia Ospedale Valduce Como
Elisabetta Corengia Neurologia Ospedale Valduce Como
Giulio Riboldazzi Neurologia Ospedale di Circolo e Fondazione Macchi Varese
Serena Leva Neurologia Ospedale di Circolo e Fondazione Macchi Varese
Alberto Priori Neurologia Fondazione Ospedale Maggiore Policlinico Milano
Filippo Cogiamanian Neurologia Fondazione Ospedale Maggiore Policlinico Milano
Gianni Pezzoli Centro Parkinson Istituti Clinici di Perfezionamento Milano
Canesi Margherita Centro Parkinson Istituti Clinici di Perfezionamento Milano
Alberto Albanese Neurologia I Fondazione IRCCS Istituto Nazionale Neurologico C.Besta; Università Cattolica del Sacro Cuore Milano
Paola Soliveri Neurologia I Fondazione IRCCS Istituto Nazionale Neurologico C.Besta Milano
Daniele Picco Neurologia Riabilitativa Fondazione Salvatore Maugeri IRCCSVeruno Veruno
Fabrizio Pisano Neurologia Riabilitativa Fondazione Salvatore Maugeri IRCCSVeruno Veruno
Leonardo Scarzella Neurologia Ospedale Evangelico Valdese Torino
Alessia Tavella Neurologia Ospedale Evangelico Valdese Torino
Leonardo Lopiano Neurologia 4 A.S.O. Molinette Torino
Maurizio Zibetti Neurologia 4 A.S.O. Molinette Torino
Michele Tinazzi U.O. Neurologia Ospedale Civile Maggiore-Borgo Trento Verona
Sarah Ottaviani U.O. Neurologia Ospedale Civile Maggiore-Borgo Trento Verona
Franco Valzanı̀a Clinica Neurologica Nuovo Ospedale Sant’Agostino-Estense Modena
Sara Contardi Clinica Neurologica Nuovo Ospedale Sant’Agostino-Estense Modena
Rocco Quatrale UO Neurologia Arcispedale Sant’Anna Ferrara
Mariachiara Sensi UO Neurologia Arcispedale Sant’Anna Ferrara
Roberto Ceravolo U.O. Neurologia Ospedale Santa Chiara Pisa
Carlo Rossi U.O. Neurologia Ospedale Santa Chiara Pisa
Massimo Cincotta Neurologia Azienda Sanitaria Firenze-S Giovanni di Dio (SGDD) Firenze
Paola Vanni Neurologia Azienda Sanitaria Firenze-S Giovanni di Dio (SGDD) Firenze
Ubaldo Bonuccelli U.O. Neurologia Ospedale Versilia Camaiore
Paolo Del Dotto U.O. Neurologia Ospedale Versilia Camaiore
Maria Gabriella Ceravolo Clinica Neuroriabilitazione Az. Ospedali Riuniti Ancona
Marianna Capecci Clinica Neuroriabilitazione Az. Ospedali Riuniti Ancona
Roberta Marchese Centro Parkinson-Dipartimento Neuroscienze Università degli Studidi Genova Genova
Tiziano Tamburini Centro Parkinson-Dipartimento Neuroscienze Università degli Studidi Genova Genova
Astrid Thomas CeSI-Centro Studi Invecchiamento Fondazione Università GabrieleD’Annunzio Chieti
Iole Borrelli CeSI-Centro Studi Invecchiamento Fondazione Università GabrieleD’Annunzio Chieti
Roberto Marconi Neurologia Ospedale della Misericordia Grosseto
Simone Gallerini Neurologia Ospedale della Misericordia Grosseto
Paolo Stanzione Clinica Neurologica Università di Roma Tor Vergata–IRCCS S Lucia Roma
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Table 4: Continued.
First name Last name Affiliation City
Valerio Pisani Clinica Neurologica Policlinico Tor Vergata Roma
Anna Rita Bentivoglio Neurologia Università Cattolica S. Cuore Policlinico Gemelli Roma
Giovanna Lor̀ıa Neurologia Università Cattolica S. Cuore Policlinico Gemelli Roma
Maria Francesca De Pandis U.O. Riabilitazione Parkinson Ospedale San Raffaele Cassino Cassino
Giovanna Federici U.O. Riabilitazione Parkinson Ospedale San Raffaele Cassino Cassino
Valentino Manzo Neurologia, Padiglione F,Amb UVA AORN A. Cardarelli Napoli
Alfonso Mauro Struttura Semplice Malattia di Parkinson AORN San Giovanni di Dioe Ruggi d’Aragona Salerno
Paolo Barone Centro Parkinson Dipartimento Scienze Neurologiche UniversitàFederico II Napoli Napoli
Marina Picillo Centro Parkinson Dipartimento Scienze Neurologiche UniversitàFederico II Napoli Napoli
Marcello Moccia Centro Parkinson Dipartimento Scienze Neurologiche UniversitàFederico II Napoli Napoli
Stefano Ruggieri Neurologia Istituto Mediterraneo Neuromed Pozzilli
Nicola Modugno Neurologia Istituto Mediterraneo Neuromed Pozzilli
Paolo Lamberti Neurologia “Amaducci” Az. Osp. Univ. Policlinico Consorziale Bari
Claudia Dell’Aquila Neurologia “Amaducci” Az. Osp. Univ. Policlinico Consorziale Bari
Giulio Cicarelli Neurologia A.O.R.N. San Giuseppe Moscati Avellino
Aldo Quattrone Clinica Neurologica Università Magna Grecia Catanzaro
Giuseppe Nicoletti Clinica Neurologica Università Magna Grecia Catanzaro
Antonino Cannas Neurologia Policlinico Universitario di Monserrato Monserrato
Paolo Solla Neurologia Policlinico Universitario di Monserrato Monserrato
Mario Zàppia Clinica Neurologica I Policlinico Universitario Catania
Alessandra Nicoletti Clinica Neurologica I Policlinico Universitario Catania
Letterio Morgante Clinica Neurologica Policlinico G. Martino Messina
Francesca Morgante Clinica Neurologica Policlinico G. Martino Messina
Marco D’Amelio Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche,Università di Palermo Palermo
Valeria Terruso Neurologia Az. Osp. Univ. Policlinico “P. Giaccone” Palermo
Roberto Eleopra SOC Neurologia Az. Osp. Univ. S.Maria della Misericordia Udine
Marco Mucchiut SOC Neurologia Az. Osp. Univ. S.Maria della Misericordia Udine
Manuela Pilleri U.O. Malattia di Parkinson IRCCS Ospedale San Camillo Venezia
Roberta Biundo U.O. Malattia di Parkinson IRCCS Ospedale San Camillo Venezia
Stefania Nassetti U.O.C. Neurologia Ospedale Bellaria Bologna
Roberto Michelucci U.O.C. Neurologia Ospedale Bellaria Bologna
APD (23.9% versus 21.3%, 𝑃 < 0.0001), compared to women
[31]. Third, since nonmotor symptoms appeared to more
heavily affect WO phenomena in women, clinicians could
be oriented to prescribe other nondopaminergic therapies,
rather than APD. Among DEEP women, the analysis of
individual WO symptoms shows the greater prevalence of
nonmotor symptoms such as “anxiety” (23.7% versus 15.2%),
“mood changes” (22.0% versus 15.5%), and “pain” (15.7%
versus 7.3%). This supports previous observations, where
women were found more likely than man to be prescribed
an antidepressant (53.1% versus 38.5%, 𝑃 < 0.0001), an
antipsychotic (19.2% versus 14.4%, 𝑃 < 0.0001), and an
anxiolytic (19.6% versus 14.7%, 𝑃 < 0.0001) [31].
Given the complexity of PD, as well as the potential
for patient characteristics to affect WO symptoms and their
management, our study allows an initial assessment of the
“gender effect” in theWOmanifestations andmanagement in
the real-world setting. Nevertheless, our study has a number
of limitations: (a) as a post hoc analysis it was not originally
designed to assess gender differences of WO symptoms; (b)
statistical analysis was mainly descriptive and 𝑃 values are
only explorative; (c) there are some limitations of the original
study, such as patients selection bias and no analysis of non-
APD medications; furthermore only symptoms included in
WOQ-19 were assessed, which precludes making assump-
tions about the contribution of other symptoms.
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In conclusion, sex differences inWOamong subjects with
PD appear to exist and may have implications for the optimal
utilization ofAPD therapy.Our results further put in perspec-
tive current clinical management of WO symptoms, raising
concern about the appropriateness of treatment approach and
also the risk of generalizing data derived from trials in which
women are often underrepresented. Further research into the
long-term implications of these disparities is needed, and
studies such as ours, although limited, suggest that “gender
effect” should be carefully considered in designing clinical
studies in PD.
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